Canada markets open in 1 hour 16 minutes

I-Mab (IMAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7200+0.1400 (+8.86%)
At close: 04:00PM EDT
1.7800 +0.06 (+3.49%)
After hours: 05:47PM EDT

I-Mab

2440 Research Boulevard
Suite 400
Rockville, MD 20850
United States
240 745 6330
https://ir.i-mabbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees220

Key Executives

NameTitlePayExercisedYear Born
Mr. Raj KannanCEO & DirectorN/AN/A1964
Mr. Skelton JosephChief Financial OfficerN/AN/A1991
Mr. Tianyi ZhangVice President of Investor RelationsN/AN/AN/A
Dr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentN/AN/AN/A
Dr. Louie Naumovski M.D., Ph.D.Interim Chief Medical OfficerN/AN/AN/A
Dr. Phillip Dennis M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Tyler EhlerSenior Director of Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Corporate Governance

I-Mab’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.